Analysis published by Novo Nordisk shows its next-generation obesity medicine CagriSema helped women lose about 25% of body weight on average in late-stage research, ahead of previously reported primary-endpoint results. The compound combines a glucagon-like peptide with a long-acting component and forms a key part of the company’s next phase in obesity treatment development.
CNBC reports Eli Lilly and Novo Nordisk are both stepping up investment in amylin pathway drugs, viewed as the next-generation core mechanism after GLP-1 obesity therapies. New clinical data shows Lilly’s experimental combination therapy outperformed Zepbound on weight loss, signaling the obesity drug race has entered a new competitive cycle.
Novo Nordisk has sued Eli Lilly, accusing the company of misleading advertising in its weight-loss drug promotion. This lawsuit marks the intensification of competition in the global weight-loss drug market, involving a battle for market share worth tens of billions of dollars.